ClinicalTrials.gg
CompletedNCT00755222Updated Oct 5, 2017Results posted

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

A Phase 2 interventional study of AA4500 and Placebo in Peyronie's Disease, sponsored by Endo Pharmaceuticals. Completed at 12 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Microbial Collagenase in Penile Induration — none open to participants now, 3 under way, none of them phase 3. Microbial Collagenase · Penile Induration.

Enrollment
5th of 13
147 · median 40
Started
2008
the only one that year
Phase 2
2 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
6 of 13
Endo Pharmaceuticals

Among the 13 studies testing Microbial Collagenase in Penile Induration, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 2, and was the 1st registered.

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

Browse Penile Induration studies →

Open to participants now

None of the 13 studies testing Microbial Collagenase in Penile Induration is open now. The open studies under Penile Induration, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Microbial Collagenase in Penile Induration as a file.
02

Study summary

This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease

Read the detailed description

A Phase 2b randomized, double-blind, placebo-controlled study of AA4500 in the treatment of subjects with Peyronie's disease.

During the screening period, subjects had a physical examination including body weight and height, vital sign measurements, a 12-lead electrocardiogram (ECG), and clinical laboratory testing. Medical history, prior and concomitant medications, and demographic data were recorded.

03

Conditions studied

  • Peyronie's Disease

Browse trials for

Keywords

  • Peyronie's disease
  • penile plaque
  • penile curvature
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterosexual male ≥ 18 years of age
  • In a stable relationship with a partner/spouse for at least 3 months before screening
  • Have a diagnosis of Peyronie's disease for at least 6 months before first dose of study drug
  • Have a penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane
  • Have functional difficulty related to Peyronie's disease (eg, difficulty with intromission or erectile dysfunction)
  • Be judged to be in good health based upon the results of medical history, physical examination and laboratory profile
  • Voluntarily sign an agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must have also signed an authorization form to allow disclosure of his protected health information. The protected health information authorization form and informed consent form may have been an integrated form or may have been separate forms, depending on the institution
  • Be able to complete and understand the various rating instruments

Exclusion criteria

Exclusion Criteria:

  • Have had an average of three successive blood pressure readings ≥ 160/100 mmHg during screening or the Day 1 assessments
  • Severe pain during penile palpation
  • Any of the following conditions:

    • Chordee in the presence or absence of hypospadias
    • Thrombosis of the dorsal penile artery
    • Infiltration by a benign or malignant mass resulting in penile curvature
    • Infiltration by an infectious agent, such as lymphogranuloma venereum
    • Ventral curvature from any cause
    • Presence of sexually transmitted disease
    • Known or C
    • Known immune deficiency disease or be positive for (HIV)
  • Previously undergone surgery for Peyronie's disease
  • Penile curvature of less than 30° or greater than 90°
  • Failed to have a rigid erection after pharmacological stimulation with a vasoactive injection of Prostaglandin E1 10 to 20 µg, which, in the opinion of the investigator, was sufficient to accurately measure the subject's penile deformity
  • Had a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray, or penile ultrasound. Non-contiguous stippling of calcium was acceptable for inclusion
  • Had an isolated hourglass deformity of the penis without curvature
  • Had the plaque causing curvature of the penis located proximal to the base of the penis, so that the injection of the local anesthetic would have interfered with the injection of AA4500 into the plaque
  • Received alternative medical therapies for Peyronie's disease administered by the intralesional route (including, but not limited to, , verapamil, and the naturally occurring low molecular weight protein, interferon-α2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  • Received alternative medical therapies for Peyronie's disease administered by the oral (including, but not limited to, vitamin E (>500IU), potassium aminobenzoate [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 4 weeks before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  • Used any mechanical type device for correction of Peyronie's disease within the 2-week period before screening or plans to use any these devices at any time during the study
  • Used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices at any time during the study
  • Significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors
  • Recent history of stroke, bleeding, or other medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  • Unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits
  • Received an drug or treatment within 30 days before the first dose of study drug
  • Allergy to collagenase or any other of AA4500
  • Allergy to any concomitant medication required as per the protocol
  • Received anticoagulant medication (except for ≤ 165 mg aspirin daily or ≤ 800 mg of over-the-counter NSAIDS daily) during the 7 days before each dose of study drug
  • Received doxycycline or a tetracycline derivative during the 7 days before each dose of study drug or plans to use these drugs within 2 days after the injection of study drug
  • Received any collagenase treatments within 30 days of the first dose of study drug
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    AA4500

    Clostridial collagenase for injection

    Biological: AA4500

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalAA4500

    2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.

    Also known as: Clostridial collagenase for injection (AA4500)

  • BiologicalPlacebo

    2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Penile Curvature

    Negative change reflects improvement in penile curvature

    Time frame: Baseline and Week 36 or last observation carried forward (LOCF)

  2. Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother

    Peyronie's disease Symptom Bother Scale: 0-20 lower numbers reflect 'less symptom bother'; higher numbers reflect 'more symptom bother' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the symptom bother scale.

    Time frame: Baseline to Week 36 or LOCF

  3. Change From Baseline in PDQ Intercourse Contraint

    Peyronie's disease intercourse contraint Scale: 0-12 lower numbers reflect 'less intercourse contraint'; higher numbers reflect 'more intercourse constraint' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse constraint scale.

    Time frame: Baseline to Week 36 or LOCF

  4. Change From Baseline in PDQ Intercourse Discomfort

    Peyronie's disease intercourse discomfort Scale: 0-15 lower numbers reflect 'less intercourse discomfort'; higher numbers reflect 'more intercourse discomfort' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse discomfort scale.

    Time frame: Baseline to Week 36 or LOCF

  5. Change From Baseline in PDQ Penile Pain

    Peyronie's disease penile pain Scale: 0-40 lower numbers reflect 'less penile pain'; higher numbers reflect 'more penile pain' Change from baseline=Week 36 minus baseline. Negative change reflects improvement in the penile pain scale.

    Time frame: Baseline to Week 36 or LOCF

07

Results

Posted Apr 26, 2011

Participant flow

Participant flow — Overall Study
MilestoneAA4500Placebo
Started11136
Completed10334
Not completed82
Withdrew: Withdrawal by subject42
Withdrew: Adverse event20
Withdrew: Protocol violation20

Outcome measures

PrimaryChange From Baseline in Penile Curvature

Negative change reflects improvement in penile curvature

Time frame:
Baseline and Week 36 or last observation carried forward (LOCF)
Reported as:
Mean · Percent change from baseline
Change From Baseline in Penile Curvature
Percent change from baselineAA4500Placebo
Change From Baseline in Penile Curvature-29.7 ± 27.16-11.0 ± 30.87
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.001
PrimaryChange From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother

Peyronie's disease Symptom Bother Scale: 0-20 lower numbers reflect 'less symptom bother'; higher numbers reflect 'more symptom bother' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the symptom bother scale.

Time frame:
Baseline to Week 36 or LOCF
Reported as:
Mean · scores on a scale
Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother
scores on a scaleAA4500Placebo
Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother-2.6 ± 4.63-0.8 ± 3.63
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.046
PrimaryChange From Baseline in PDQ Intercourse Contraint

Peyronie's disease intercourse contraint Scale: 0-12 lower numbers reflect 'less intercourse contraint'; higher numbers reflect 'more intercourse constraint' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse constraint scale.

Time frame:
Baseline to Week 36 or LOCF
Reported as:
Mean · scores on a scale
Change From Baseline in PDQ Intercourse Contraint
scores on a scaleAA4500Placebo
Change From Baseline in PDQ Intercourse Contraint-1.5 ± 3.31-0.7 ± 3.65
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.164
PrimaryChange From Baseline in PDQ Intercourse Discomfort

Peyronie's disease intercourse discomfort Scale: 0-15 lower numbers reflect 'less intercourse discomfort'; higher numbers reflect 'more intercourse discomfort' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse discomfort scale.

Time frame:
Baseline to Week 36 or LOCF
Reported as:
Mean · scores on a scale
Change From Baseline in PDQ Intercourse Discomfort
scores on a scaleAA4500Placebo
Change From Baseline in PDQ Intercourse Discomfort-0.8 ± 3.46-0.4 ± 4.27
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.442
PrimaryChange From Baseline in PDQ Penile Pain

Peyronie's disease penile pain Scale: 0-40 lower numbers reflect 'less penile pain'; higher numbers reflect 'more penile pain' Change from baseline=Week 36 minus baseline. Negative change reflects improvement in the penile pain scale.

Time frame:
Baseline to Week 36 or LOCF
Reported as:
Mean · scores on a scale
Change From Baseline in PDQ Penile Pain
scores on a scaleAA4500Placebo
Change From Baseline in PDQ Penile Pain-2.4 ± 6.32-0.5 ± 5.30
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.095

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500—4/111 (3.6%)109/111 (98.2%)
Placebo—1/36 (2.8%)28/36 (77.8%)
Most frequent serious events
Most frequent serious events
EventAA4500Placebo
OsteoarthritisMusculoskeletal and connective tissue disorders0/1111/36
ArthritisMusculoskeletal and connective tissue disorders1/1110/36
Chest painGeneral disorders1/1110/36
DehydrationMetabolism and nutrition disorders1/1110/36
HypotensionVascular disorders1/1110/36
SepsisInfections and infestations1/1110/36
Neck painMusculoskeletal and connective tissue disorders1/1110/36
Road traffic accidentInjury, poisoning and procedural complications1/1110/36
Most frequent other events
Most frequent other events
EventAA4500Placebo
Injection site bruisingGeneral disorders100/11118/36
Injection site painGeneral disorders61/1115/36
Injection site edemaGeneral disorders55/1110/36
ContusionInjury, poisoning and procedural complications25/1112/36
Penile edemaReproductive system and breast disorders14/1111/36
Penile painReproductive system and breast disorders14/1110/36
Painful erectionReproductive system and breast disorders7/1111/36
General disorder maleReproductive system and breast disorders6/1112/36
Peyronie's diseaseReproductive system and breast disorders0/1112/36
Injection site pruritusGeneral disorders6/1110/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500PlaceboTotal
<=18 years000
Between 18 and 65 years9534129
>=65 years16218
Age, Continuous
Age, Continuous(years)AA4500PlaceboTotal
Mean56.9 ± 7.7955.4 ± 6.9556.6 ± 7.60
Sex: Female, Male
Sex: Female, Male(Participants)AA4500PlaceboTotal
Female000
Male11136147
Region of Enrollment
Region of Enrollment(participants)AA4500PlaceboTotal
United States11136147
08

Study locations

12 sites
  • Urology Associates Medical Group
    Burbank, California 91505, United States
  • Urology Specialists Connecticut Clinical Research Center, LLC
    Middlebury, Connecticut 06762, United States
  • The Urology Center, PC
    New Haven, Connecticut 06511, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Urology Specialists, SC
    Chicago, Illinois 60612, United States
  • Northeast Indiana Research, LLC
    Fort Wayne, Indiana 46825, United States
  • Metropolitan Urology, PSC
    Jeffersonville, Indiana 47130, United States
  • Maimonides Medical Center Divison of Urology
    Brooklyn, New York 11219, United States
  • University Urology Associates
    New York, New York 10016, United States
  • Tristate Urologic Services
    Cincinnati, Ohio 45212, United States
  • Baylor College of Medicine, Scott Department of Urology
    Houston, Texas 77030, United States
  • Urology of Virginia (a division of Sentara Medical Group)
    Norfolk, Virginia 23502, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2008
First posted
Sep 18, 2008
Start
Aug 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Apr 26, 2011
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00755222
Responsible party
Sponsor
First posted
Sep 18, 2008
Start date
Aug 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Apr 26, 2011
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion